Luping Zhao

发表

A randomized phase II study of paclitaxel and bevacizumab with and without gemcitabine as first-line treatment for metastatic breast cancer.

C. Obasaju, J. Hainsworth, A. Brufsky, 2011, Clinical breast cancer.

Phase III trial of induction gemcitabine or paclitaxel plus carboplatin followed by paclitaxel consolidation in ovarian cancer.

C. Obasaju, M. Janicek, M. Orlando, 2011, Gynecologic oncology.

Study protocol: systematic review and meta-analysis of randomized controlled trials in first-line treatment of squamous non-small cell lung cancer

S. Able, F. Natanegara, L. Bowman, 2014, Systematic Reviews.

Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer

Edward S. Kim, N. Reinmuth, M. Ahn, 2020, JAMA oncology.

Comparison of KRAS genotype: therascreen assay vs. LNA-mediated qPCR clamping assay.

C. Horak, E. Van Cutsem, J. Denne, 2013, Clinical colorectal cancer.

Durvalumab with or without tremelimumab vs platinum-based chemotherapy as first-line treatment for metastatic non-small cell lung cancer: MYSTIC

N. Reinmuth, M. Ahn, S. Peters, 2018, Annals of Oncology.

Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: Results of a Phase II, randomized, noncomparative study

C. Obasaju, D. Richards, L. Wilfong, 2011, Investigational New Drugs.

950 Final analysis: phase 1b study investigating intratumoral injection of toll-like receptor 9 agonist vidutolimod ± pembrolizumab in patients with PD-1 blockade–refractory melanoma

D. Davar, J. Kirkwood, A. Ribas, 2021, Journal for ImmunoTherapy of Cancer.

Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin (FOLFOX4) as first-line therapy for patients with advanced colorectal cancer

C. Leichman, P. Ritch, D. Waterhouse, 2012, Investigational New Drugs.

Phase III trial of gemcitabine plus docetaxel (GD) compared to capecitabine plus docetaxel (CD) with planned crossover to the alternate single agent in metastatic breast cancer (MBC)

M. DeRuiter, C. V. D. Velde, A. Seidman, 2009 .